Andrea R. Filippi, Associate Professor of Radiation Oncology at the University of Milan. Chair of Radiotherapy Department at Istituto Nazionale Tumori, shared a post on X:
“In this academic phase 2 trial, reducing thoracic RT from 60 to 45 Gray after chemotherapy-IO is feasible for frailer, unfit patients with stage III NSCLC. Thanks to patients, families, co-investigators, and the external sponsor.”
Title: Sequential chemo-durvalumab, reduced dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial)
Authors: Francesco Agustoni, Jessica Saddi, Diego Luigi Cortinovis, Stefano Arcangeli, Luca Sala, Catherine Klersy, Valeria Musella, Giulia Galli, Sabrina Borgetto, Giulia Maria Stella, Daniela Cicognini, Alessandra Ferrari, Paolo Pedrazzoli, Francesco Grossi, Andrea Riccardo Filippi.
Other articles featuring Andrea R. Filippi on OncoDaily.